Cancer survival appears to double with common vaccine, researchers say
PositiveU.S News

A recent study has revealed that combining the COVID vaccine with immunotherapy could significantly enhance cancer survival rates, nearly doubling the average lifespan of patients from 20.6 months to 37.3 months. This finding is crucial as it opens new avenues for cancer treatment, potentially offering hope to many patients and their families. The implications of this research could lead to more effective treatment protocols and improved outcomes for those battling cancer.
— Curated by the World Pulse Now AI Editorial System













